Does Dr. FAWZI ABU ROUS have financial conflicts of interest?

Dr. FAWZI ABU ROUS (MD) has received a total of $10,916 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $10,916 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. FAWZI ABU ROUS?

According to CMS Open Payments data, Dr. FAWZI ABU ROUS received funding from DAIICHI SANKYO ($2,055), E.R. SQUIBB & SONS, L.L.C ($2,014), and ASTRAZENECA PHARMACEUTICALS ($1,885).

Does Dr. FAWZI ABU ROUS receive research grants or speaking fees?

Dr. FAWZI ABU ROUS has received $10,916 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. FAWZI ABU ROUS

MDReal-Time Hydrated

Specialty: Internal Medicine, Medical Oncology

Practice Location: LANSING, MI 48912

NPI Number: 1992226575

LIFETIME INDUSTRY VALUE

$10,916

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABU ROUS is a verified Internal Medicine, Medical Oncology practitioner based in LANSING, MI.

Between 2021 and 2024, Dr. ABU ROUS had an overall industry promotional and research financial footprint of $10,916 as recorded in the federal CMS Open Payments database.

$10,916 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABU ROUS's primary funding source is DAIICHI SANKYO, which accounts for $2,055 (representing 18.8% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

DAIICHI SANKYO

Rank 1

$2,055

18.8%

E.R. SQUIBB & SONS, L.L.C

Rank 2

$2,014

18.4%

ASTRAZENECA PHARMACEUTICALS

Rank 3

$1,885

17.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.